Clinical Trials
23 trialsNCT03866382 2026-06-03
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04461509 2026-03-25
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03333616 2026-01-21
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06680089 2025-12-31
CD70-targeted immunoPET Imaging of Kidney Cancer
RenJi Hospital
Phase 2 Recruiting
NCT06353906 2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05935748 2025-11-12
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Phase 2 Terminated
NCT06237920 2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT02266745 2024-04-05
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Promontory Therapeutics Inc.
Phase 2 Unknown
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT04784507 2022-04-12
En-Bloc Resection of Bladder Tumors
Medipol University
Phase 2 Unknown
NCT04221828 2022-03-29
Trial of NanoPac Focal Therapy for Prostate Cancer
NanOlogy, LLC
Phase 2 Terminated
NCT05030077 2021-09-01
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT04644432 2020-11-25
INDIGO
Herlev and Gentofte Hospital
Phase 2 Unknown
NCT02060370 2020-02-27
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01094496 2020-02-13
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
Celldex Therapeutics
Phase 2 Terminated
NCT03077659 2019-08-20
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
NanOlogy, LLC
Phase 2 Completed
NCT00672009 2018-10-24
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT01316458 2017-06-01
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
Novartis
Phase 2 Completed
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT00707356 2016-04-19
Study of WST11 in Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 2 Completed
NCT01599013 2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2 Completed
NCT00975429 2015-04-28
Study Using WST11 in Patients With Localized Prostate Cancer
Steba Biotech S.A.
Phase 2 Completed
NCT00134186 2007-03-05
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Pharmacyclics LLC.
Phase 2 Completed